Novo Nordisk

Patient using blood pressure monitor
#Cardiovascular disease #Novo Nordisk #Obesity #University College London #Weight loss

Ozempic could be a gamechanger for cardiovascular disease

Semaglutide (the active ingredient in Wegovy and Ozempic) can produce clinically meaningful weight loss and delivers significant cardiovascular benefits, according to two studies presented at the European Congress on Obesity (ECO). The studies are based on the Semaglutide and Cardiovascular Outcomes (SELECT) trial, the largest and… Read More

#News #Trending News

Novo Nordisk head office
#Cardior Pharmaceuticals #Cardiovascular disease #Mergers and acquisitions #Novo Nordisk

Novo Nordisk acquires cardiovascular therapies developer

Novo Nordisk has acquired Cardior Pharmaeuticals for up to €1.025 billion, including an upfront payment and additional payments if certain milestones are achieved. Cardior is focused on the discovery and development of therapies that target RNA to prevent, repair and reverse diseases of the heart. The company seeks to advance… Read More

#Business & Investment #News

Stock market
#Diabetes #Eli Lilly #GlobalData #Market reporting #Novo Nordisk #Vertex #Weight loss

Lilly, Novo Nordisk and Vertex lead on market capitalisation growth

The top 20 global biopharmaceutical companies have reported 1.6% market capitalisation growth to $3.67 trillion in 2023, according to data analysts GlobalData. The top 20 global biopharmaceutical companies experienced varied year-on-year (YoY) market capitalisation shifts in 2023 amid the macroeconomic headwinds, steep patent cliffs and the commencement of US drug… Read More

#Business & Investment #News

Cardiovascular system
#Cardiovascular disease #Diabetes #Novo Nordisk #Obesity #Phase III trial

Semaglutide reduces major cardiovascular events by 20%

Semaglutide 2.4mg (Wegovy), a drug approved for weight loss, can reduce the risk of major adverse cardiovascular events (MACE) by 20%, according to new data released by Novo Nordisk. SELECT is a Phase III cardiovascular outcomes trial investigating the effects of once-weekly semaglutide 2.4mg in adults… Read More

#News #Trending News

Ozempic Insulin injection pen
#Alzheimer's #Dementia #Nicotine addiction #Novo Nordisk #Type 2 diabetes

Could GLP-1 receptor agonists like Ozempic treat addiction and dementia?

Medications containing semaglutide such as Ozempic, licensed for diabetes, and Wegovy, for weight loss, are being studied to see if they can treat a range of different conditions, including addiction and dementia. Semaglutide manufacturer Novo Nordisk reported earlier this month that the drug reduces the risk… Read More

#News #Trending News

Novo Nordisk head office
#ABPI #Association of the British Pharmaceutical Industry #Novo Nordisk #Pharmaceutical industry #UK

Novo Nordisk suspended from UK’s ABPI membership

Novo Nordisk has been suspended as a member of the Association of the British Pharmaceutical Industry (ABPI) for two years due to serious breaches of the ABPI Code of Practice. This is the eighth occasion in the past 40 years the ABPI Board has issued such… Read More

#News

Women in Life Science Denmark
#Denmark #Diversity #Gender equality #Life sciences #Novo Nordisk #Scandinavia

Danish women’s network promotes diversity in life sciences

A science-centric network for women in senior positions across industry and academia has launched in Denmark to strengthen the life sciences industry and promote talent, diversity and inclusiveness.   Women in Life Science Denmark (WiLD) has received support from the Novo Nordisk Foundation, contributing €56,000 ($60,293) over the… Read More

#News

Blood cells
#Haemophilia #Interview #Novo Nordisk #Rare disease

Novo Nordisk: positivity for haemophilia treatment  

DDW Editor Reece Armstrong speaks to Stephanie Seremetis, Chief Medical Officer, Rare Blood Disorders at Novo Nordisk to get her response to the company's latest study results for its Mim8 antibody. Earlier this year, pharmaceutical company Novo Nordisk announced positive results from Phase I & II clinical trials investigating its… Read More

#Exclusive Content #Opinion

Woman with a nose bleed
#Haemophilia #Novo Nordisk #Rare disease

Novo Nordisk announces positive results for haemophilia A antibody  

Novo Nordisk has announced positive interim results for its Mim8 antibody which is being as a treatment for haemophilia A.   Novo Nordisk presented interim results from the Phase I & II FRONTIER1 dose-escalation study at International Society of Thrombosis and Haemostasis Annual Congress… Read More

#News

Haemophilia
#Clinical trials #Novo Nordisk

Novo Nordisk announces positive results for haemophilia treatment  

Pharmaceutical company Novo Nordisk has announced positive results for its prophylactic treatment targeting people living with haemophilia A or B with inhibitors.   The company’s concizumab treatment is an anti-tissue factor pathway inhibitor (TFPI) antibody in development to prevent prolonged and spontaneous bleeding in all types of… Read More

#News